Acute lymphoblastic leukemia: Optimizing treatment strategies in children

Pediatric Drugs

Volumn 4, Issue 6, 2002, Pages 405-416

  Vora, Ajay ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLUCOCORTICOID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCA ALKALOID; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; GREAT BRITAIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; RANDOMIZED CONTROLLED TRIALS;

EID: 0036084199     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204060-00007     Document Type: Review

References (62)

1. Treatment of acute lymphoblastic leukemia: 30 Years' experience at St. Jude Children's Research Hospital
2. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86
3. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia
4. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia
5. Antimicrotubule agents
6. Continuous vincristine infusion as part of a high dose chemotherapy regimen: Drug kinetics and toxicity
7. Vincristine pharmacokinetics after repetitive dosing in children
8. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group
9. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
10. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL)
11. The use of glucocorticoids in acute lymphoblastic leukemia of childhood: Molecular, cellular, and clinical considerations
12. Varying prednisolone dosage in remission induction of previously untreated childhood leukemia
13. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs
14. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
15. Use of L-asparaginase in childhood ALL
16. Pharmacokinetics and drug monitoring of L-asparaginase treatment
17. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
18. Pegylated asparaginase (Oncaspar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols
19. Anthracyclines and anthracenediones
20. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
21. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
22. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion
23. Cyclophosphamide pharmacokinetics in children
24. Results of treatment of advanced stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and co-ordinated high dose methotrexate and cytarabine
25. Ode to methotrexate
26. Receptor and carrier-mediated transport systems for folates and antifolates
27. Polyglutamation of methotrexate: Is methotrexate a prodrug?
28. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues: Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumour cells
29. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance
30. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia
31. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia: New insights from the lab and clinic
32. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis
33. Reversal of methylmercaptopurine ribonucleoside cytotoxicity by purine ribonucleosides and adenine
34. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase
35. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
36. Childhood leukaemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia
37. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia
38. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3 A4
39. Human cytochrome P450 metabolism of teniposide and etoposide
40. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
41. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
42. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites
43. Kinetic and template studies with 1-b-D-arabinofuranosylcytosine-5-triphosphate and mammalian deoxyribonucleic and polymerase
44. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-b-D-arabinofuranosyladenine
45. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia
46. Report to the Medical Research Council by the Working Party on Leukaemia in Childhood. Treatment of acute lymphoblastic leukaemia: Effect of variation in length of treatment on duration of remission
47. Testicular irradiation in childhood lymphoblastic leukaemia
48. Medical Research Council leukaemia trial. UKALL V: An attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood
49. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 randomised children
50. Report to the Council by the Working Party on Leukaemia in Childhood, 1972-84 Improvement in treatment for children with acute lymphoblastic leukaemia: The Medical Research Council UKALL trials
51. Results of Medical Research Council leukaemia trial UKALL VIII. Report to the Medical Research Council on behalf of the working party on leukaemia in childhood
52. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
53. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials
54. Comparison of high dose methotrexate with continuing intrathecal methotrexate versus intrathecal methotrexate alone in low white blood count childhood acute lymphoblastic leukaemia: Preliminary results from the UKALLXI randomised trial
55. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: A comparison of haematological toxicity and drug metabolite concentrations
56. Gender and treatment outcome in childhood lymphoblastic leukaemia: Report from the MRC UKALL trials
57. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: Results of MRC UKALL X
58. Acute lymphoblastic leukaemia in infancy: Experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia
59. Cytoreduction and prognosis in acute lymphoblastic leukemia: The importance of early marrow response. Report from the Childrens Cancer Group
60. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
61. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study
62. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance